The BioIndustry Association (BIA)’s ongoing engagement enables our members’ voices to be heard at the highest levels. This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from April to July 2019.
The BIA has responded to the House of Commons Science and Technology Select Committee’s inquiry on commercial genomics.
In late June, the BIA sent this briefing to UK MEPs as they prepared to take up their seats in the European Parliament.
The BIA has submitted views to the Labour Party's Economy, Business and Trade Commission to inform its policy development.
The BIA has submitted views to the Labour Party's Health and Social Care Commission to inform its policy development.
This BioIndustry Association/Informa biotech financing update provides data on sector fundraising from March to May 2019.
The newly updated guide ‘What is a biosimilar medicine?’ was developed by NHS England, in partnership with BIA and key organisations including MHRA, NICE, ABPI and RPS. This document provides an update for key clinical and non-clinical stakeholders about the role of biosimilar medicines in the NHS in England and to support the safe, effective and consistent use of all biological medicines, including biosimilar medicines, to the benefit of patients, in line with the principles of shared decision-making to ensure individuals are supported to make decisions that are right for them - www.england.nhs.uk/shared-decision-making.
This report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.
The BIA has responded to the Convention on Biological Diversity (CBD) Secretariat’s consultation on Digital Sequence Information (DSI) on Genetic Resources.